In a recent study from the CALERIE trial, researchers applied proteomics to plasma samples from participants who achieved an average of **14% caloric restriction (CR) over two years, revealing significant insights into the impact of CR on human aging and healthspan. The analysis demonstrated that CR leads to a notable reduction in the complement component C3a, a key player in the inflammatory response, thereby mitigating inflammaging—the chronic, low-grade inflammation associated with aging. Specifically, the C3a/C3 ratio was significantly lowered, indicating a shift in the inflammatory landscape that is crucial for understanding aging mechanisms.**

The findings underscore the therapeutic potential of targeting the complement system to enhance healthspan. The study identified a non-senescent age-associated macrophage subset in visceral fat as a primary source of C3a production, highlighting the role of macrophages in age-related inflammation. Intra-adipose administration of a C3a-specific neutralizing antibody effectively reduced inflammaging in mice, suggesting that similar strategies could be developed for human applications. Moreover, CR was shown to positively influence other metabolic markers, such as increasing **adiponectin and decreasing leptin, further supporting the notion that CR can rewire metabolic pathways toward longevity.**

The implications of this research are significant for the field of aging biology. By elucidating the mechanisms through which CR alters the complement pathway and reduces inflammation, this study provides a concrete target for future therapeutic interventions aimed at extending healthspan. The identification of **C3a as a metabolically regulated inflammatory checkpoint opens avenues for drug development that could mimic CR’s beneficial effects without the need for dietary restrictions, potentially accelerating the timeline for clinical applications in aging-related diseases.**

Source: nature.com